Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Arlene Chan; D. W. Miles; Xavier Pivot

doi:10.1093/annonc/mdq122

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Arlene Chan ^{1, 2} D. W. Miles ^{1, 3} Xavier Pivot ^{1, 4}

1 Service d'oncologie Médicale

2 Medical Oncology

3 Medical Oncology

4 HOTE GREFFON - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)

Abstract : Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity. Ongoing trials are investigating the efficacy and safety of bevacizumab in various stages of breast cancer and in breast cancer with a range of hormonal or receptor characteristics.

Type de document :

Article dans une revue

Annals of Oncology, Oxford University Press (OUP), 2010, 21 (12), pp.2305-15. 〈10.1093/annonc/mdq122〉

Domaine :

Sciences du Vivant [q-bio] / Immunologie

Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00484825
Contributeur : Philippe Saas <>
Soumis le : mercredi 19 mai 2010 - 11:54:14
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Métriques

77

Contact

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Partager

Métriques

77

Contact